OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 2.0 %

Shares of OPGN opened at $0.48 on Thursday. The stock’s 50-day moving average price is $0.57 and its 200 day moving average price is $0.49. OpGen has a 12-month low of $0.17 and a 12-month high of $3.84. The firm has a market capitalization of $6.08 million, a price-to-earnings ratio of -0.07 and a beta of -0.56.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.